Ketamine for the treatment of depression in patients receiving hospice care: a retrospective medical record review of thirty-one cases.
Ketamine for the treatment of depression in patients receiving hospice care: a retrospective medical record review of thirty-one cases.
复制标题
DOI：
10.1016/j.psym.2014.05.005
复制
发表时间：
2015-07
期刊：
影响因子：
3.4
通讯作者：
Irwin, Scott A.
中科院分区：
文献类型：
--
作者：
Iglewicz, Alana;Morrison, Katherine;Nelesen, Richard A.;Zhan, Tingting;Iglewicz, Boris;Fairman, Nathan;Hirst, Jeremy M.;Irwin, Scott A.
Depression is prevalent in patients receiving hospice care. Standard antidepressant medications do not work rapidly enough in this setting. Evidence suggests that ketamine rapidly treats treatment refractory depression in the general population. Ketamine’s role for treating depression in the hospice population warrants further study. A retrospective chart review of 31 inpatients receiving hospice care who received ketamine for depression on a clinical basis was conducted. The primary outcome measure was the Clinical Global Impression Scale, which was used retrospectively to rate subjects’ therapeutic improvement, global improvement, and side effects from ketamine over 21 days. Additionally, time to onset of therapeutic effect was also analyzed. Using the CGI, ketamine was found to be significantly therapeutically effective through the first week after ketamine dosing (p < 0.05), with 93% of subjects showing positive results for days 0 – 3 and 80% for days 4 – 7 post ketamine dosing. Subjects experienced global improvement during all four time periods post ketamine dosing (all p-values < 0.05). Significantly more subjects had either no side effects or side effects that did not significantly impair functioning at each of the four assessed time periods post ketamine dosing (all p-values < 0.05). Additionally, significantly more subjects experienced their first therapeutic response during days 0–1 post ketamine dosing (p < 0.001) than during any other time period. These data suggest that ketamine may be a safe, effective, and rapid treatment for clinical depression in patients receiving hospice care. Blinded, randomized, and controlled trials are required to substantiate these findings and support further clinical use of this medication in hospice settings.
登录
查看更多内容
DOI：
10.1177/104990910101800610
发表时间：
2001-11-01
期刊：
The American journal of hospice & palliative care
影响因子：
--
作者：
Homsi, J;Nelson, K A;Walsh, D
通讯作者：
Walsh, D
影响因子：
45.3
作者：
Bruera, E;Driver, L;Escalante, C
通讯作者：
Escalante, C
DOI：
10.2190/16fh-9ect-y280-vv45
发表时间：
1995-01-01
影响因子：
2
作者：
FERNANDEZ, F;LEVY, JK;RUIZ, P
通讯作者：
RUIZ, P
影响因子：
10.6
作者：
aan het Rot, Marije;Collins, Katherine A.;Mathew, Sanjay J.
通讯作者：
Mathew, Sanjay J.
DOI：
10.4088/jcp.09m05327blu
发表时间：
2010-12
期刊：
The Journal of clinical psychiatry
影响因子：
--
作者：
DiazGranados N;Ibrahim LA;Brutsche NE;Ameli R;Henter ID;Luckenbaugh DA;Machado-Vieira R;Zarate CA Jr
通讯作者：
Zarate CA Jr